MO Stock Analysis: Altria | NYSE
Tobacco | NYSE, USA | Market Cap: 119.881m USD | 12M Return: 34.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 512M
EPS Trend: 93.9%
Qual. Beats: 1
Rev. Trend: 33.3%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Altria Group is a major U.S. tobacco company headquartered in Richmond, Virginia, founded in 1822. The company manufactures and sells a portfolio of smokeable and oral tobacco products, with its flagship Marlboro cigarette brand dominating the U.S. cigarette market. Beyond cigarettes, Altria offers large cigars and pipe tobacco (Black & Mild), moist smokeless tobacco and traditional oral products (Copenhagen, Skoal, Red Seal, Husky), oral nicotine pouches (on!), and e-vapor products (NJOY ACE). Its products are distributed through wholesale distributors and large retail chains.
As a Consumer Staples company in the GICS Tobacco sub-industry, Altria operates in a heavily regulated sector with strict marketing restrictions and ongoing litigation exposure. The tobacco industry has long faced secular volume declines in traditional cigarettes, prompting major producers to invest in reduced-risk products such as nicotine pouches and e-vapor as potential growth areas, though these categories remain smaller than legacy tobacco lines.
- Marlboro cigarette volumes decline as smoking rates fall
- On! oral nicotine pouches gain share against Zyn
- FDA moves toward menthol cigarette ban and oral pouch approval
| Net Income: 8.05b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.25 > 0.02 and ΔFCF/TA 1.30 > 1.0 |
| NWC/Revenue: -17.10% < 20% (prev -22.60%; Δ 5.50% < -1%) |
| CFO/TA 0.26 > 3% & CFO 8.89b > Net Income 8.05b |
| Net Debt (21.1b) to EBITDA (11.9b): 1.78 < 3 |
| Current Ratio: 0.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.67b) vs 12m ago -1.01% < -2% |
| Gross Margin: 67.84% > 18% (prev 70.81%; Δ -2.97% > 0.5%) |
| Asset Turnover: 62.02% > 50% (prev 56.62%; Δ 5.41% > 0%) |
| Interest Coverage Ratio: 10.83 > 6 (EBIT TTM 11.6b / Interest Expense TTM 1.07b) |
| A: -0.11 (Total Current Assets 4.68b - Total Current Liabilities 8.41b) / Total Assets 34.6b |
| B: 1.04 (Retained Earnings 35.9b / Total Assets 34.6b) |
| C: 0.33 (EBIT TTM 11.6b / Avg Total Assets 35.2b) |
| D: -0.09 (Book Value of Equity -3.21b / Total Liabilities 37.7b) |
| Altman-Z'' = 4.81 = AA |
| DSRI: 1.02 (Receivables 284.0m/258.0m, Revenue 21.8b/20.2b) |
| GMI: 1.04 (GM 70.81% / 67.84%) |
| AQI: 1.04 (AQ_t 0.81 / AQ_t-1 0.79) |
| SGI: 1.08 (Revenue 21.8b / 20.2b) |
| TATA: -0.02 (NI 8.05b - CFO 8.89b) / TA 34.6b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of July 22, 2026, the stock is trading at USD 74.66 with a total of 6,709,162 shares traded. Over the past week, the price has changed by +3.88%, over one month by +4.26%, over three months by +17.27% and over the past year by +34.33%.
Current recommended Stop Loss: 72.30 (which is 3.2% or 1.3 ATR below the current price).
Altria has received a consensus analysts rating of 3.38. Therefore, it is recommended to hold MO.
- StrongBuy: 4
- Buy: 0
- Hold: 7
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 70.6 | -5.4% |
P/E Trailing = 14.9875
P/E Forward = 12.8205
P/S = 5.8829
P/B = 25.2407
P/EG = 1.6435
Revenue TTM = 21.8b USD
EBIT TTM = 11.6b USD
EBITDA TTM = 11.9b USD
Long Term Debt = 24.1b USD (from longTermDebt, last quarter)
Short Term Debt = 542.0m USD (from shortTermDebt, last quarter)
Debt = 24.6b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.1b USD (calculated: Debt 24.6b - CCE 3.53b)
Enterprise Value = 141b USD (120b + Debt 24.6b - CCE 3.53b)
Interest Coverage Ratio = 10.83 (Ebit TTM 11.6b / Interest Expense TTM 1.07b)
EV/FCF = 16.35x (Enterprise Value 141b / FCF TTM 8.62b)
FCF Yield = 6.12% (FCF TTM 8.62b / Enterprise Value 141b)
FCF Margin = 39.53% (FCF TTM 8.62b / Revenue TTM 21.8b)
Net Margin = 36.91% (Net Income TTM 8.05b / Revenue TTM 21.8b)
Gross Margin = 67.84% ((Revenue TTM 21.8b - Cost of Revenue TTM 7.02b) / Revenue TTM)
Gross Margin QoQ = 64.59% (prev 62.11%)
Tobins Q-Ratio = 4.08 (Enterprise Value 141b / Total Assets 34.6b)
Interest Expense / Debt = 4.37% (Interest Expense 1.07b / Debt 24.6b)
Taxrate = 23.78% (2.51b / 10.6b)
NOPAT = 8.87b (EBIT 11.6b * (1 - 23.78%))
Current Ratio = 0.56 (Total Current Assets 4.68b / Total Current Liabilities 8.41b)
Debt / Equity = -7.66 (negative equity) (Debt 24.6b / totalStockholderEquity, last quarter -3.21b)
Debt / EBITDA = 1.78 (Net Debt 21.1b / EBITDA 11.9b)
Debt / FCF = 2.44 (Net Debt 21.1b / FCF TTM 8.62b)
Total Stockholder Equity = -3.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 22.90% (Net Income 8.05b / Total Assets 34.6b)
RoE = -255.3% (negative equity) (Net Income TTM 8.05b / Total Stockholder Equity -3.15b)
RoCE = 55.68% (EBIT 11.6b / Capital Employed (Equity -3.15b + L.T.Debt 24.1b))
RoIC = 34.62% (NOPAT 8.87b / Invested Capital 25.6b)
WACC = 4.56% (E(120b)/V(144b) * Re(4.81%) + D(24.6b)/V(144b) * Rd(4.37%) * (1-Tc(0.24)))
Discount Rate = 4.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.04 | Cagr: -2.43%
[DCF] Terminal Value 75.71% ; FCFF base≈8.55b ; Y1≈8.73b ; Y5≈9.57b
[DCF] Fair Price = 76.19 (EV 148b - Net Debt 21.1b = Equity 127b / Shares 1.67b; r=8.35% [WACC [floored]]; 5y FCF grow 2.04% → 2.50% )
EPS Correlation: 93.93 | EPS CAGR: 4.61% | SUE: 2.30 | # QB: 1
Revenue Correlation: 33.25 | Revenue CAGR: 0.79% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.50 | Chg30d=+0.27% | Revisions=+73% | Analysts=11
EPS next Quarter (2026-09-30): EPS=1.51 | Chg30d=+0.09% | Revisions=-18% | Analysts=11
EPS current Year (2026-12-31): EPS=5.68 | Chg30d=+0.09% | Revisions=+79% | GrowthEPS=+4.9% | GrowthRev=+2.0%
EPS next Year (2027-12-31): EPS=5.88 | Chg30d=+0.06% | Revisions=+79% | GrowthEPS=+3.4% | GrowthRev=+0.7%
[Analyst] Revisions Ratio: +68% (up=33, down=5)